FDA amends pembrolizumab’s gastric cancer indication
On November 7, 2023, the Food and Drug Administration revised the existing indication of pembrolizumab with…
Browsing: gastroesophageal junction
ASCO 2019: Front-line pembrolizumab is promising alternative to chemotherapy for advanced gastroesophageal junction and gastric cancers
The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients…